百奥赛图-B2022年度报告

Stock code 股份代號：2315百奧賽圖北京醫藥科技股份有限公司Biocytogen Pharmaceuticals (Beijing) Co., Ltd.(A joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司）Annual Report年度報告 2022 11百奧賽圖(北京)醫藥科技股份有限公司 二零二二年年報目錄 Contents主席報告2Chairman’s Statement管理層討論與分析6Management Discussion and Analysis董事、監事及高級管理層46Directors, Supervisors and Senior Management企業管治報告62Corporate Governance Report董事會報告87Directors’ Report環境、社會及管治報告132Environmental, Social and Governance Report附錄一：環境關鍵績效指標摘要171Appendix I: Environmental Key Performance Indicators Summary Table附錄二：聯交所《環境、社會及管治報告指引》索引173Appendix II: Index of HKEX’s Environmental, Social and Governance Reporting Guide獨立核數師報告179Independent Auditor’s Report綜合損益及其他全面收入表186Consolidated Statements of Profit or Loss and Other Comprehensive Income綜合財務狀況表187Consolidated Statements of Financial Position綜合權益變動表189Consolidated Statements of Changes in Equity綜合現金流量表190Consolidated Cash Flow Statements綜合財務報表附註193Notes to the Consolidated Financial Statements財務概要3 11Financial Summary釋義312Definition公司資料325Corporate Information 2Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Annual Report 2022主席報告 Chairman’s StatementDear distinguished shareholders,First of all, I would like to express my heartfelt gratitude to all of you for trusting and supporting Biocytogen. I am delighted to announce on behalf of the Board the Company’s first annual report for the year ended December 31, 2022.In 2022, Biocytogen reaped inspiring results bucking multiple challenges in the external environment. We saw a hike in operating revenue, a continuous stream of technological innovations and accelerating global cooperation, and secured listing on the Main Board of the Hong Kong Stock Exchange in September. In the annual report, we are very pleased to share with you Biocytogen’s results for 2022 and the outlook for 2023.VIGOROUS PUSH FOR OVERSEAS MARKETS, WITH PRE-CLINICAL BUSINESS BURGEONINGOur overseas business burgeoned in 2022, thanks to our solid underlying technology and pre-clinical products and services that persistently contribute to R&D in global pharmaceutical companies. Original gene editing technology and high-efficiency teams enable us to develop hundreds of distinctive and innovative animal and cell models every year. We never stop looking for new clients, tapping into new regions and expanding overseas markets for pre-clinical research. By the end of 2022, we had cumulatively developed more than 2,800 models to provide important tools for scientific research and drug evaluation, and offered more than 2,000 pre-clinical pharmacology and efficacy evaluation services to over 400 clients globally. We have faith that the business segment will stay fast-growing.尊敬的各位股東，感謝各位股東對百奧賽圖的信任和支持。本人代表董事會，欣然呈上公司截至2022年12月31日的首份年度報告。2022年儘管外部環境面對諸多挑戰，百奧賽圖仍然取得了令人振奮的成績，我們的營業收入大幅增長，技術不斷創新，全球合作持續加速，並於9月成功在香港聯合交易所主板上市。在本次年報中，我們很高興與閣下分享百奧賽圖在2022年的成績，以及對2023年的展望。積極拓展海外市場，臨床前業務增長迅速2022年我們的海外業務呈現出高速增長，扎實的底層技術和臨床前產品服務持續賦能全球藥企的藥物開發。原創的基因編輯技術和高效的團隊，使我們能保持每年開發數百種獨特且創新的基因編輯動物和細胞模型，我們持續開拓新客戶、新地區，拓展海外臨床前研究市場，截至2022年底累計我們已經開發出2800餘種模型來為科學研究及藥物評估提供重要工具，已為全球400多個客戶提供2000餘項臨床前藥理藥效服務。相信在未來該業務仍將保持高速增長。 33百奧賽圖(北京)醫藥科技股份有限公司 二零二二年年報主席報告 Chairman’s Statement技術創新，千鼠萬抗進展順利我們的核心全人抗體RenMice平台，在2022年迎來新的成員RenNano小鼠，這一小鼠的成功研發將帶領我們拓寬至全人單域抗體與納米抗體的開發領域。基於專有的大片段基因編輯SUPCE技術，我們已經建立了RenMab、RenLite、RenNano和TCRm等系列全人抗體技術平台，為單抗、雙抗、多抗、雙抗ADC、TCRm抗體、細胞治療、納米抗體等多藥物形式研發提供強大的支撐。以RenMice平台為基礎的「千鼠萬抗」計劃進展順利，預計到2023年三季度，公司將完成「千鼠萬抗」的大部分工作，預計將獲得覆蓋1000多個創新靶點的40-50萬個全人抗體序列庫，能夠滿足各類合作藥企不同的抗體開發需求。PURSUE TECHNOLOGICAL INNOVATIONS, WITH PROJECT INTEGRUM GOING SMOOTHLYIn 2022, our RenMice platform for generating fully human antibodies embraced a new member, namely the mouse RenNano, which will broaden our R&D to fully human monoclonal antibodies and nanobodies. On the back of the proprietary SUPCE technology for large segment gene editing, we have set up a raft of platforms for fully human antibodies including RenMab, RenLite, RenNano and TCRm, which can enormously underpin R&D of drug forms of many sorts such as monoclonal antibodies, bispecific antibodies, polyclonal antibodies, bispecific antibody ADC, TCRm antibodies, cell therapy and nanoantibody, etc.Dependent on the RenMice platform, Project Integrum is making steady progress. The Company expects to get the bulk of the project done by the third quarter of 2023, and to generate 400,000-500,000 fully human antibody sequences for more than 1,000 innovative targets, which can cater to the antibody development needs of pharmaceutical companies of all kinds. 4Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Annual Report 2022主席報告Chairman’s StatementSEEK BUSINESS COOPERATION, WITH